DXB Share Price, page-62

Well- interim had 3/11 "responders", so worst case from here is 3/27.. at greater than 50% reduction on standard of care; even 3/27 or 11% is pretty good.. at Ph2b they will have patients on the most effective dose(s) for longer and have a better selected patient population which are more likely to show benefit to this drug combination.. so unless there is a major safety issue (which is very unlikely because they would have to have disclosed it under continuous disclosure) the results we know are already good. if they can achieve at least 6/27 at 50% or greater, ie >22% - I think that is a fantastic result. Shows the first 3 weren't flukes! My 2c+ prediction is only because I have lost some faith that the market will release its full value prior to a licensing deal..